ImmunityBio, Inc. (IBRX)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
ImmunityBio’s third fiscal quarter of 2026 results missed consensus on both revenue and adjusted EPS, as reported November 9, 2026, even as sales grew sharply year over year. Revenue rose 52.3% to roughly $48.8 million (up from about $32.1 million a year ago) but trailed expectations, coming in at $48.8 million versus a $59.2 million estimate (-17.5%). Adjusted EPS of -$0.17 also trailed the -$0.07 estimate by -$0.10 and was down from -$0.07 a year ago. Profitability remained pressured despite a gross margin of about 97%, with gross profit of roughly $47.5 million alongside an operating loss of about $78.0 million, translating to an operating margin near -160%. Net income was a loss of roughly $184.6 million, compared with a loss of about $67.3 million a year ago (-174.4%). For the next period, consensus calls for EPS of -$0.10 on revenue of $62.5 million.
About ImmunityBio, Inc.
ImmunityBio, Inc. (NASDAQ: IBRX) is a biotechnology company that develops therapies and vaccines for cancer and infectious disease using immunotherapy and cell therapy platforms. In FY2025, it generated $113.3 million in revenue. Its programs span antibody-cytokine fusion proteins, immunomodulators, vaccine technologies, NK cell therapies, and T-cell strategies.
Today's Snapshot
IBRX closed 7% higher at 6.70, outperforming a weaker sector.
Trading Volume
Below 10d avg (17.2M)
15.6M
vs S&P 500 Today
Strong Outperformance
+7.29%
Updated: November 18, 2026 at 21:09 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$6.81 - $8.03Sell
- RSI (14)40.71Neutral
- Stochastic %K (14, 3, 3)17.35Buy
- MACD Level (12, 26)-0.70Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.